{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:05:50Z","timestamp":1790175950103,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comprehensive Psychiatry"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.comppsych.2019.152114","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:01:48Z","timestamp":1565002908000},"page":"152114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia"],"prefix":"10.1016","volume":"94","author":[{"given":"Peiyan","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.comppsych.2019.152114_bb0005","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","article-title":"The endophenotype concept in psychiatry: etymology and strategic intentions","volume":"160","author":"Gottesman","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0015","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1371\/journal.pmed.0020212","article-title":"The genetics of schizophrenia","volume":"2","author":"Sullivan","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.comppsych.2019.152114_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/342734","article-title":"Neuregulin 1 and susceptibility to schizophrenia","volume":"71","author":"Stefansson","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.comppsych.2019.152114_bb0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ajmg.b.30275","article-title":"The involvement of ErbB4 with schizophrenia: association and expression studies","volume":"141B","author":"Silberberg","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.comppsych.2019.152114_bb0030","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajmg.b.30236","article-title":"Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia","volume":"141B","author":"Norton","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.comppsych.2019.152114_bb0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn2392","article-title":"Neuregulin 1 in neural development, synaptic plasticity and schizophrenia","volume":"9","author":"Mei","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0040","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1073\/pnas.0910302107","article-title":"Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons","volume":"107","author":"Wen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.comppsych.2019.152114_bb0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/schbul\/sbq051","article-title":"Migration, ethnicity, and psychosis: toward a sociodevelopmental model","volume":"36","author":"Morgan","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2019.152114_bb0050","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00213-013-3424-y","article-title":"Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of \u2018schizophrenia-like\u2019 behaviour in the rat","volume":"231","author":"Gaskin","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S1461145710001239","article-title":"Vulnerability in early life to changes in the rearing environment plays a crucial role in the aetiopathology of psychiatric disorders","volume":"14","author":"Niwa","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0060","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.biopsych.2006.05.008","article-title":"Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?","volume":"59","author":"Powell","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0031-9384(99)00082-7","article-title":"Ontogeny of isolation rearing-induced deficits in sensorimotor gating in rats","volume":"67","author":"Bakshi","year":"1999","journal-title":"Physiol Behav"},{"key":"10.1016\/j.comppsych.2019.152114_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s002130100810","article-title":"Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies","volume":"156","author":"Braff","year":"2001","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.comppsych.2019.152114_bb0075","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijdevneu.2016.03.001","article-title":"Early life adversities or high fat diet intake reduce cognitive function and alter BDNF signaling in adult rats: interplay of these factors changes these effects","volume":"50","author":"Arcego","year":"2016","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0085","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1126\/science.1226931","article-title":"Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids","volume":"339","author":"Niwa","year":"2013","journal-title":"Science."},{"key":"10.1016\/j.comppsych.2019.152114_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/bmm.13.83","article-title":"The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients","volume":"8","author":"Guest","year":"2014","journal-title":"Biomark Med"},{"key":"10.1016\/j.comppsych.2019.152114_bb0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pneurobio.2014.08.002","article-title":"Applications of blood-based protein biomarker strategies in the study of psychiatric disorders","volume":"122","author":"Chan","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2174\/1871527311312050010","article-title":"Neuropeptide systems and schizophrenia","volume":"12","author":"LaCrosse","year":"2013","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.comppsych.2019.152114_bb0105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?","volume":"11","author":"Griebel","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.comppsych.2019.152114_bb0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bcp.2011.10.014","article-title":"Peptide therapeutics for CNS indications","volume":"83","author":"McGonigle","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0115","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1111\/j.1460-9568.2006.05151.x","article-title":"Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons","volume":"24","author":"Jomphe","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0031-6997(24)01509-6","article-title":"Neurotensin and dopamine interactions","volume":"53","author":"Binder","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.comppsych.2019.152114_bb0125","doi-asserted-by":"crossref","first-page":"21818","DOI":"10.1073\/pnas.1010669107","article-title":"ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation","volume":"107","author":"Chen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.comppsych.2019.152114_bb0130","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.1523\/JNEUROSCI.2204-14.2014","article-title":"Parvalbumin and GAD65 interneuron inhibition in the ventral hippocampus induces distinct behavioral deficits relevant to schizophrenia","volume":"34","author":"Nguyen","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.comppsych.2019.152114_bb0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.57.6.609","article-title":"Prepulse inhibition of the startle response in men with schizophrenia: effects of age of onset of illness, symptoms, and medication","volume":"57","author":"Kumari","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0145","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1176\/appi.ajp.157.10.1660","article-title":"Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits","volume":"157","author":"Cadenhead","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0150","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1176\/ajp.150.12.1862","article-title":"Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder","volume":"150","author":"Cadenhead","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1176\/ajp.156.4.596","article-title":"Symptom correlates of prepulse inhibition deficits in male schizophrenic patients","volume":"156","author":"Braff","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0160","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.schres.2013.12.004","article-title":"Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS","volume":"152","author":"Swerdlow","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fnbeh.2016.00202","article-title":"Reduced prepulse inhibition as a biomarker of schizophrenia","volume":"10","author":"Mena","year":"2016","journal-title":"Frontiers in behavioral neuroscience"},{"key":"10.1016\/j.comppsych.2019.152114_bb0170","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/sj.mp.4002068","article-title":"Endophenotypes in psychiatric genetics","volume":"12","author":"Walters","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0175","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.mp.4001159","article-title":"Mouse genetic models for prepulse inhibition: an early review","volume":"7","author":"Geyer","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0180","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/sj.mp.4002046","article-title":"Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration","volume":"13","author":"McOmish","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0166-4328(02)00185-7","article-title":"Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity","volume":"136","author":"Eells","year":"2002","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00213-013-3011-2","article-title":"The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats","volume":"228","author":"McIntosh","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0200","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1016\/S0021-9258(19)43429-7","article-title":"The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami","volume":"248","author":"Carraway","year":"1973","journal-title":"J Biol Chem"},{"key":"10.1016\/j.comppsych.2019.152114_bb0205","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0304-3940(90)90721-K","article-title":"Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: in vivo release of dopamine and neurotensin from rat prefrontal cortex","volume":"108","author":"Bean","year":"1990","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.comppsych.2019.152114_bb0210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0306-4522(00)90023-X","article-title":"Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens","volume":"98","author":"Sotty","year":"2000","journal-title":"Neuroscience."},{"key":"10.1016\/j.comppsych.2019.152114_bb0215","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1176\/ajp.139.9.1122","article-title":"Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment","volume":"139","author":"Widerlov","year":"1982","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.npep.2016.05.001","article-title":"Gene-environment interactions in a rat model of depression. Maternal separation affects neurotensin in selected brain regions","volume":"59","author":"Ellenbroek","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.comppsych.2019.152114_bb0225","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1126\/science.6136092","article-title":"Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia","volume":"221","author":"Nemeroff","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.comppsych.2019.152114_bb0230","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/syn.21907","article-title":"Sex differences in neurotensin and substance P following nicotine self-administration in rats","volume":"70","author":"Pittenger","year":"2016","journal-title":"Synapse."},{"key":"10.1016\/j.comppsych.2019.152114_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-3565(24)38888-3","article-title":"Sex- and estrous cycle-related differences in the effects of acute antipsychotic drug administration on neurotensin-containing neurons in the rat brain","volume":"295","author":"Kinkead","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.comppsych.2019.152114_bb0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/187152706776359655","article-title":"Novel treatments of schizophrenia: targeting the neurotensin system","volume":"5","author":"Kinkead","year":"2006","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.comppsych.2019.152114_bb0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0074-7742(04)59013-X","article-title":"Neurotensin, schizophrenia, and antipsychotic drug action","volume":"59","author":"Kinkead","year":"2004","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0250","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0255","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbr.2009.09.044","article-title":"Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance","volume":"207","author":"Briody","year":"2010","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0260","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tips.2011.03.007","article-title":"Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal","volume":"32","author":"Sakurai","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0265","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/schbul\/sbm088","article-title":"Schizophrenia, hypocretin (orexin), and the thalamocortical activating system","volume":"33","author":"Lambe","year":"2007","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.comppsych.2019.152114_bb0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2009.10.068","article-title":"Convergent actions of orexin\/hypocretin and CRF on dopamine neurons: emerging players in addiction","volume":"1314","author":"Borgland","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0275","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuroscience.2012.02.036","article-title":"Orexin signaling in the paraventricular thalamic nucleus modulates mesolimbic dopamine and hedonic feeding in the rat","volume":"210","author":"Choi","year":"2012","journal-title":"Neuroscience."},{"key":"10.1016\/j.comppsych.2019.152114_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-1781(02)00032-X","article-title":"CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture","volume":"110","author":"Nishino","year":"2002","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2014.12.012","article-title":"Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms","volume":"53","author":"Chien","year":"2015","journal-title":"Psychoneuroendocrinology."},{"key":"10.1016\/j.comppsych.2019.152114_bb0290","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/sj.mp.4001363","article-title":"Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects","volume":"8","author":"Dalal","year":"2003","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0295","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002","article-title":"Differential activation of orexin neurons by antipsychotic drugs associated with weight gain","volume":"22","author":"Fadel","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.comppsych.2019.152114_bb0300","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/npp.2009.119","article-title":"Orexin\/hypocretin in psychiatric disorders: present state of knowledge and future potential","volume":"35","author":"Borgland","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0305","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3109\/15622975.2012.677547","article-title":"Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study","volume":"14","author":"Montag","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.comppsych.2019.152114_bb0310","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0306-4530(85)90056-3","article-title":"Vasopressin\u2013oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls","volume":"10","author":"Beckmann","year":"1985","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0315","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/0306-4530(92)90019-4","article-title":"Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics","volume":"17","author":"Legros","year":"1992","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.comppsych.2019.152114_bb0320","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2007.09.019","article-title":"Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits","volume":"98","author":"Goldman","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0325","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2012.06.016","article-title":"Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia","volume":"139","author":"Sasayama","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0330","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/dev.21202","article-title":"Neuroendocrine responses to social isolation and paternal deprivation at different postnatal ages in Mandarin voles","volume":"56","author":"Wang","year":"2014","journal-title":"Dev Psychobiol"},{"key":"10.1016\/j.comppsych.2019.152114_bb0335","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2016.04.019","article-title":"Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: a post-mortem study","volume":"177","author":"Uhrig","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.comppsych.2019.152114_bb0340","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0920-9964(94)90021-3","article-title":"Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication","volume":"11","author":"Glovinsky","year":"1994","journal-title":"Schizophr Res"}],"container-title":["Comprehensive Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X19300379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010440X19300379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T18:34:56Z","timestamp":1757874896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010440X19300379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":68,"alternative-id":["S0010440X19300379"],"URL":"https:\/\/doi.org\/10.1016\/j.comppsych.2019.152114","relation":{},"ISSN":["0010-440X"],"issn-type":[{"value":"0010-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Comprehensive Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.comppsych.2019.152114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152114"}}